Table 1.
Baseline characteristics
| Patient characteristics | N = 83 |
|---|---|
| Age, median (range), years | 57.0 (30–78) |
| ≥ 65 years, % | 19 |
| Male, % | 70 |
| KPS, % | |
| 90–100 | 70 |
| 70–80 | 30 |
| Current site(s) of metastasis, % | |
| Hepatic/liver | 83 |
| Abdomen/peritoneal | 53 |
| Lung/thoracic | 18 |
| No. of metastatic sites, % | |
| 1 | 35 |
| 2 | 43 |
| 3 | 19 |
| 4 | 2 |
| CA 19–9, median (range), U/mLa | 602.8 (0.93–1000) |
| Biliary stent, % | 1 |
a CA 19–9 value above laboratory-defined upper limit of quantitation (1000 U/mL) is listed as 1000 U/mL
CA 19–9 carbohydrate antigen 19–9, KPS Karnofsky performance status